Zacks Investment Research upgraded shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) from a sell rating to a hold rating in a report issued on Tuesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

A number of other research firms have also weighed in on CAPR. HC Wainwright assumed coverage on shares of Capricor Therapeutics in a report on Wednesday, July 6th. They issued a buy rating and a $13.00 target price on the stock. Roth Capital assumed coverage on shares of Capricor Therapeutics in a report on Wednesday, June 15th. They issued a buy rating and a $12.00 target price on the stock.

Capricor Therapeutics (OTCMKTS:CAPR) opened at 3.57 on Tuesday. Capricor Therapeutics has a 12-month low of $1.88 and a 12-month high of $5.40. The company’s market cap is $64.10 million. The company’s 50-day moving average price is $3.69 and its 200-day moving average price is $3.46.

Capricor Therapeutics (OTCMKTS:CAPR) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.02. Equities analysts anticipate that Capricor Therapeutics will post ($1.04) earnings per share for the current year.

A hedge fund recently raised its stake in Capricor Therapeutics stock. Vanguard Group Inc. raised its stake in Capricor Therapeutics Inc (OTCMKTS:CAPR) by 25.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,975 shares of the company’s stock after buying an additional 5,704 shares during the period. Vanguard Group Inc. owned 0.16% of Capricor Therapeutics worth $111,000 at the end of the most recent quarter.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease, with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development, which include CAP-1002, CAP-1001, CSps, Exosomes, Cenderitide (CD-NP) and CU-NP.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.